Apogee Therapeutics released Phase II maintenance data showing its IL‑13 antibody zumilokibart maintained high response rates with dosing every three or six months. The company reported durable EASI‑75 responses at one year—75% for three‑month dosing and 85% for six‑month dosing in selected cohorts—prompting investor enthusiasm and a sharp share move. Apogee claims the regimen could offer more convenient maintenance than current IL‑13/IL‑4 inhibitors and is positioning the asset against established therapies from Regeneron, Sanofi and Lilly. The data will need confirmation in larger trials to determine whether the dosing advantage translates into market differentiation.